High-resolution gene expression profiling using RNA sequencing in patients with inflammatory bowel disease and in mouse models of colitis

Journal of Crohn's and Colitis

Volumn 9, Issue 6, 2015, Pages 492-506

  Holgersen, Kristine ^a,d   Kutlu, Burak ^b   Fox, Brian ^b   Serikawa, Kyle ^b   Lord, James ^c   Hansen, Axel Kornerup ^d   Holm, Thomas Lindebo ^a  

^a NOVO NORDISK A S   (Denmark)

^b NOVO NORDISK INC   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Experimental colitis; Interleukin 10 knockout mouse; RNA sequencing

Indexed keywords

CALGRANULIN A; CALGRANULIN B; COMPLEMENT COMPONENT C3; CR2 PROTEIN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; DECAY ACCELERATING FACTOR; DEFB1 PROTEIN; DEXTRAN SULFATE; EOTAXIN; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 23 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRILYSIN; MULTIDRUG RESISTANCE PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; PROTEIN; REG1A PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; RNA; TRANSCRIPTOME;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HELPER CELL; HUMAN; HUMAN TISSUE; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; ULCERATIVE COLITIS; UPREGULATION; WEIGHT CHANGE; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-10; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; PIROXICAM; RNA; SEQUENCE ANALYSIS, RNA; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTOME;

EID: 84963734168     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv050     Document Type: Article

References (88)

1. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011;365:1612-23.
2. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
3. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
4. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
5. Shih DQ, Targan SR. Insights into IBD pathogenesis. Curr Gastroenterol Rep 2009;11:473-80.
6. Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000;4:1-11.
7. Granlund A, Flatberg A, Ostvik AE, et al. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One 2013;8:e56818.
8. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
9. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380:1590-605.
10. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
11. Solomon L, Mansor S, Mallon P, et al. The dextran sulphate sodium [DSS] model of colitis: an overview. Comp Clin Pathol 2010;19:235-9.
12. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
13. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
14. Kjellev S, Lundsgaard D, Poulsen SS, Markholst H. Reconstitution of Scid mice with CD4+CD25-T cells leads to rapid colitis: An improved model for pharmacologic testing. Int Immunopharmacol 2006;6:1341-54.
15. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993;178:237-44.
16. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-71.
17. Holgersen K, Kvist PH, Markholst H, Hansen AK, Holm TL. Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse: A model mimicking inflammatory bowel disease. J Crohns Colitis 2013;8:147-60.
18. Holgersen K, Kvist PH, Hansen AK, Holm TL. Predictive validity and immune cell involvement in the pathogenesis of piroxicam-accelerated colitis in interleukin-10 knockout mice. Int Immunopharmacol 2014;21:137-47.
19. Nicklas W, Baneux P, Boot R, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002;36:20-42.
20. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:267-76.
21. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction [RT-PCR]. Clin Exp Immunol 1995;101:428-35.
22. Scarpa M, Behboo R, Angriman I, et al. The role of costimulatory molecules CD80 and CD86 and IFNgamma in the pathogenesis of ulcerative colitis. Dig Dis Sci 2004;49:1738-44.
23. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445-56.
24. Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013;62:967-76.
25. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Digest Dis Sci 1992;37:818-26.
26. Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008;57:1398-405.
27. Noble CL, Abbas AR, Lees CW, et al. Characterization of intestinal gene expression profiles in Crohn's disease by genome-wide microarray analysis. Inflamm Bowel Dis 2010;16:1717-28.
28. Christophi GP, Rong R, Holtzapple PG, Massa PT, Landas SK. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2012;18:2342-56.
29. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001;48:326-32.
30. Autschbach F, Funke B, Katzenmeier M, Gassler N. Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver: an immunohistochemical analysis with new monoclonal antibodies from the 8th International Workshop and Conference on human leucocyte differentiation antigens. Cell Immunol 2005;236:110-14.
31. Tornehave D, Zahn S, Matthiesen F, Krogh BO, Lundsgaard, D. IL-21 and IL-21 receptor expression in the intestine from patients with Crohn's disease. In: Poster presentations: Basic Science, European Crohn's and Colitis Organisation, Feb14-16, 2013; Vienna.
32. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005;129:969-84.
33. Song L, Zhou R, Huang S, et al. High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease. Mediators Inflamm 2013;2013:425915.
34. Seidelin JB, Coskun M, Kvist PH, Holm TL, Holgersen K, Nielsen OH. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol 2015;50:180-90.
35. Spalinger MR, Lang S, Weber A, et al. Loss of protein tyrosine phosphatase nonreceptor type 22 regulates interferon-G-induced signaling in human monocytes. Gastroenterology 2013;144:978-88.
36. Mariani P, Bachetoni A, D'Alessandro M, Lomanto D, Mazzocchi P, Speranza V. Effector Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disease. Dig Dis Sci 2000;45:2029-35.
37. Roman LI, Manzano L, De La Hera A, Abreu L, Rossi I, Alvarez-Mon M. Expanded CD4+CD45RO+ phenotype and defective proliferative response in T lymphocytes from patients with Crohn's disease. Gastroenterology 1996;110:1008-19.
38. Chen Z, Brant SR, Li C, et al. CTLA4-1661A/G and 3'UTR long repeat polymorphisms are associated with ulcerative colitis and influence CTLA4 mRNA and protein expression. Genes Immun 2010;11:573-83.
39. Repnik K, Potocnik U. CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease patients and regulates expression of CTLA4 isoforms. DNA Cell Biol 2010;29:603-10.
40. Scarpa M, Bortolami M, Cecchetto A, et al. Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitis. Eur J Cancer 2011;47:611-19.
41. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T Cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 2007;132:2346-58.
42. Connor SJ, Paraskevopoulos N, Newman R, et al. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 2004;53:1287-94.
43. Arijs I, De HG, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011;106:748-61.
44. Uguccioni M, Gionchetti P, Robbiani DF, et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am JPathol 1999;155:331-6.
45. Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003;199:28-35.
46. Puleston J, Cooper M, Murch S, et al. A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:109-20.
47. Labbe C, Boucher G, Foisy S, et al. Genome-wide expression profiling implicates a MAST3-regulated gene set in colonic mucosal inflammation of ulcerative colitis patients. Inflamm Bowel Dis 2012;18:1072-80.
48. Arijs I, De HG, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009;4:e7984.
49. Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest 2008;88:1110-20.
50. Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 2001;281:G216-28.
51. Coskun M, Troelsen JT, Nielsen OH. The role of CDX2 in intestinal homeostasis and inflammation. Biochim Biophys Acta 2011;1812:283-9.
52. de Bruyn M, Machiels K, Vandooren J, et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:339-52.
53. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
54. Rath T, Roderfeld M, Graf J, et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 2006;12:1025-35.
55. Algaba A, Linares PM, Fernández-Contreras ME, et al. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohn's Colitis 2013:e569-79.
56. Candia E, Díaz-Jiménez D, Langjahr P, et al. Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients. Immunobiology 2012;217:634-42.
57. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005;129:50-65.
58. Andoh A, Fujiyama Y, Kimura T, et al. Increased expression of decayaccelerating factor [CD55] in the inflamed mucosa of patients with ulcerative colitis. Pathophysiology 1998;5:105-10.
59. Sugihara T, Kobori A, Imaeda H, et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010;160:386-93.
60. Barnett MP, McNabb WC, Cookson AL, et al. Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. BMC Immunol 2010;11:39.
61. Russ AE, Peters JS, McNabb WC, et al. Gene expression changes in the colon epithelium are similar to those of intact colon during late inflammation in interleukin-10 gene deficient mice. PLoS One 2013;8:e63251.
62. Te Velde AA, de KF, Sterrenburg E, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 2007;13:325-30.
63. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004;344:37-51.
64. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003;60:569-80.
65. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 2013;8:197-210.
66. Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012;18:6782-9.
67. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-8.
68. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One 2012;7:e44328.
69. Ostvik AE, Granlund AV, Torp SH, et al. Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol 2013;173:502-11.
70. Thomas DD, Ridnour LA, Isenberg JS, et al. The chemical biology of nitric oxide: Implications in cellular signaling. Free Radic Biol Med 2008;45:18-31.
71. Sohn JJ, Schetter AJ, Yfantis HG, et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS One 2012;7:e44156.
72. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004;113:427-37.
73. Dhillon SS, Mastropaolo LA, Murchie R, et al. Higher activity of the inducible nitric oxide synthase contributes to very early onset inflammatory bowel disease. Clin Transl Gastroenterol 2014;5:e46.
74. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P. Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000;279:G90-9.
75. Krieglstein CF, Anthoni C, Cerwinka WH, et al. Role of blood-and tissueassociated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol 2007;170:490-6.
76. Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene [GRO] alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996;271:20545-50.
77. Atreya R, Neurath MF. Chemokines in inflammatory bowel diseases. Dig Dis 2010;28:386-94.
78. Bain CC, Mowat AM. The monocyte-macrophage axis in the intestine. Cell Immunol 2014;291:41-8.
79. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun 2011;3:550-64.
80. Turk R, 'T Hoen PA, Sterrenburg E, et al. Gene expression variation between mouse inbred strains. BMC Genomics 2004;5:57.
81. Holgersen K, Dobie R, Farquharson C, et al. Piroxicam treatment augments bone abnormalities in interleukin-10 knockout mice. Inflamm Bowel Dis 2015;21:257-66.
82. Tarlton JF, Whiting CV, Tunmore D, et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 2000;157:1927-35.
83. Hansen CH, Nielsen DS, Kverka M, et al. Patterns of early gut colonization shape future immune responses of the host. PLoS One 2012;7:e34043.
84. Reading NC, Kasper DL. The starting lineup: key microbial players in intestinal immunity and homeostasis. Front Microbiol 2011;2:148.
85. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
86. Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002;123:1527-42.
87. Hale LP, Gottfried MR, Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis 2005;11:1060-69.
88. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.